2SEVENTY BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.255 USD | -0.82% |
|
-5.86% | -0.35% |
| Apr. 19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
| Apr. 05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 598.9 | 355.3 | 216.2 | 218.7 | - | - |
| Enterprise Value (EV) 1 | 333.9 | 89.01 | 216.2 | 218.7 | 218.7 | 218.7 |
| P/E ratio | -2.06 x | -1.31 x | -0.97 x | -2.09 x | -6.1 x | -12.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11 x | 3.88 x | 2.15 x | 2.47 x | 1.9 x | 1.99 x |
| EV / Revenue | 11 x | 3.88 x | 2.15 x | 2.47 x | 1.9 x | 1.99 x |
| EV / EBITDA | -2.01 x | -1.41 x | -0.95 x | -1.67 x | -3.42 x | -6.44 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 1.68 x | 1.14 x | 0.82 x | 1.53 x | 1.46 x | - |
| Nbr of stocks (in thousands) | 23,369 | 37,917 | 50,625 | 51,405 | - | - |
| Reference price 2 | 25.63 | 9.370 | 4.270 | 4.255 | 4.255 | 4.255 |
| Announcement Date | 3/22/22 | 3/16/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 54.52 | 91.5 | 100.4 | 88.57 | 115 | 109.8 |
| EBITDA 1 | - | -297.6 | -251.6 | -227.3 | -130.9 | -64.05 | -33.96 |
| EBIT 1 | - | -313.9 | -263.1 | -237.6 | -127.2 | -64.84 | -43.95 |
| Operating Margin | - | -575.82% | -287.6% | -236.69% | -143.57% | -56.36% | -40.03% |
| Earnings before Tax (EBT) 1 | - | -292.2 | -254.2 | -217.6 | -130.1 | -62.21 | -36.8 |
| Net income 1 | -120.1 | -292.2 | -254.2 | -217.6 | -96.17 | -31.3 | -17.69 |
| Net margin | - | -535.95% | -277.77% | -216.73% | -108.59% | -27.21% | -16.11% |
| EPS 2 | -5.000 | -12.44 | -7.130 | -4.420 | -2.034 | -0.6970 | -0.3519 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 10/8/21 | 3/22/22 | 3/16/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19.26 | 16.03 | 8.429 | 13.48 | 13.41 | 56.18 | 41.62 | 36.05 | 12.03 | 10.68 | 14.09 | 17.2 | 22.25 | 23.67 |
| EBITDA 1 | -60.57 | - | - | - | - | - | - | -45.75 | - | -56.91 | -37.29 | -24.48 | -14.81 | -11.27 |
| EBIT 1 | -65.24 | -68.37 | -90.59 | -76.97 | -68.37 | -27.21 | -51.71 | -47.99 | -57.3 | -59.94 | -47.27 | -39.23 | -29.12 | -22.87 |
| Operating Margin | -338.78% | -426.44% | -1,074.72% | -570.92% | -509.9% | -48.44% | -124.25% | -133.13% | -476.13% | -560.99% | -335.57% | -228.04% | -130.88% | -96.62% |
| Earnings before Tax (EBT) 1 | -60 | -60.97 | -85.71 | -77.4 | -67.88 | -23.14 | -47.02 | -42.09 | -71.64 | -56.82 | -44.9 | -34.21 | -26.94 | -16.29 |
| Net income 1 | -60 | -60.97 | -85.71 | -77.42 | -67.88 | -23.14 | -47.02 | -42.09 | -71.64 | -56.82 | -41 | -29.54 | -15.34 | -10.31 |
| Net margin | -311.58% | -380.3% | -1,016.86% | -574.25% | -506.26% | -41.2% | -112.97% | -116.76% | -595.3% | -531.84% | -291.07% | -171.75% | -68.97% | -43.55% |
| EPS 2 | - | -2.550 | -3.200 | -2.020 | -1.760 | -0.6000 | -1.080 | -0.8300 | -1.400 | -1.110 | -0.8122 | -0.6302 | -0.3620 | -0.2691 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/1/21 | 3/22/22 | 5/12/22 | 8/10/22 | 11/7/22 | 3/16/23 | 5/3/23 | 8/14/23 | 11/14/23 | 3/5/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 265 | 266 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -135% | -75.8% | -76.9% | -41.6% | -6.78% | -11.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 15.30 | 8.190 | 5.180 | 2.790 | 2.920 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 11.6 | 22.8 | 13.9 | 12.4 | 13 | - |
| Capex / Sales | - | 21.23% | 24.97% | 13.81% | 14.02% | 11.33% | - |
| Announcement Date | 10/8/21 | 3/22/22 | 3/16/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.255
USD
Average target price
11
USD
Spread / Average Target
+158.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.35% | 219M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TSVT Stock
- Financials 2seventy bio, Inc.
